Pricing Log in Create free account
Friday 6 November 2026 Export IBRX’s income statement to Excel — free account

ImmunityBio, Inc.

IBRX Healthcare Biotechnology

ImmunityBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $113.3 million, up 668.3% from fiscal 2024.

Revenue
+93.9%
EPS
−120.0%
Free cash flow
+13.4%
Total debt
+57.4%

Quarter to June 2026, against a year earlier

8.51 0.50 +6.24%
Market cap
$8.5B
P/E
0.0×
Fwd P/E
−8.7×
Dividend yield
—
F-score
4/9
Altman Z
−10.16
Beneish M
4.57
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

ImmunityBio, Inc. (IBRX) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, ImmunityBio, Inc. (IBRX) trades at a P/S ratio of 51.0×. Over the past ten years it has ranged from 0.1× (March 2015) to 26,332× (February 2021); the current reading is higher than 11% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

P/S ratio, daily

Embed this chart

Annual newest first

Period P/S ratio Change
FY2025 16.1× (86.72%)
FY2024 121× (97.17%)
FY2023 4,285× (46.09%)
FY2022 7,948× 213.68%
FY2021 2,534× (69.50%)
FY2020 8,308× 1,217.67%
FY2019 631× (67.72%)
FY2018 1,953× (75.10%)
FY2017 7,844× (28.77%)
FY2016 11,011× 109.66%

Quarterly newest first

Period P/S ratio Change
Jun 2026 55.5× (0.69%)
Mar 2026 55.9× 247.50%
Dec 2025 16.1× (43.00%)
Sep 2025 28.2× (31.91%)
42 more quarters

Against its own ten years

Low 0.1× High 26,332×
Ten-year median 2,734×
Current reading's percentile 7

P/S ratio against peers

Company P/S ratio
CAI Caris Life Sciences,�Inc. compare 7.1×
MDGL Madrigal Pharmaceuticals, Inc. compare 8.2×
TGTX TG Therapeutics, Inc. compare 10.3×
TWST Twist Bioscience Corporation compare 17.6×
KRYS Krystal Biotech, Inc. compare 18.9×
PTGX Protagonist Therapeutics, Inc. compare 31.7×
IBRX ImmunityBio, Inc. 51.0×
CYTK Cytokinetics, Incorporated compare 64.4×
SYRE Spyre Therapeutics, Inc. compare 8,160×
Biotechnology industry median 9.2×
Healthcare sector median 3.5×
Market median 1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

More on IBRX